SAB BIOTHERAPEUTICS, INC. Capital Expenditures Incurred but Not yet Paid
SAB BIOTHERAPEUTICS, INC. (SABS) reported Capital Expenditures Incurred but Not yet Paid of $102.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2026-06-30 was -$153.38K.
- SAB BIOTHERAPEUTICS, INC. capital expenditures incurred but not yet paid for the quarter ending 2026-03-31 was $255.38K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month |
|---|---|---|
| 2026-06-30 | -$153.38K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $102.00K 10-Q · filed 2026-08-06 |
| 2026-03-31 | $255.38K 10-Q · filed 2026-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |